By Daniel Webster, dWeb.News Publisher
TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM“) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, announces that Mr. Sergio Martines has resigned from the board of directors of the Company. We wish Mr. Martines all the best in his future endeavours.
About RAMM Pharma Corp.
RAMM is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products with a unique and diversified international production and sales platform. The Company is a well-established pharmaceutical and medical product company in Uruguay. It has produced a number of medically approved and registered plant-derived cannabinoid products which have been licensed for sale in many Latin American countries. RAMM has a pipeline that includes registered cannabis-based nutrition products and specialized veterinarian products. These products are in various stages and approvals. They are produced at RAMM’s Good Manufacturing Practice (GMP), certified cannabis formulation plant in Montevideo, Uruguay. RAMM’s vertically integrated European operations are located in Ragusa in Italy. They include a hemp cultivation platform and large extraction and processing facilities. In the final stages, they will be able to produce a wide range of CBD Formulations, APIs and wellness products. There will also be two retail stores that sell its Marishanti cosmetics line.
RAMM Pharma Corp. includes its wholly owned subsidiaries Canapar Corp., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.
Additional information about the Company is available at http://www.RAMMpharma.com.
For further information, please contact:
Chief Operating Officer of RAMM
+598 92 223 131
For more dWeb.News Business News: https://dweb.news/news-sections/business-news/